文献速递肾小球疾病慢性肾脏病

全国队列研究提示克隆靶向化疗对免疫触须样肾小球病远期结局良好

Results of a nation-wide cohort study suggest favorable long-term outcomes of clone-targeted chemotherapy in immunotactoid glomerulopathy.
PubMed 文献 · Kidney Int · 2020-07-30

该法国回顾性全国队列纳入19年间21个肾内科的27例成人免疫触须样肾小球病患者,评估克隆靶向化疗的长期结局。中位随访40个月后,21例接受化疗者中18例获肾脏缓解,16例维持缓解,7例达终末期肾病,6例死亡。早期诊断及血液学缓解与良好结局相关。

要点

  • 免疫触须样肾小球病常伴慢性/小淋巴细胞淋巴瘤等克隆性疾病。
  • 克隆靶向化疗后血液学缓解与肾脏良好结局相关。
  • 需完善病理及血液学检查以指导管理。

核心结论

  • 早期诊断和克隆靶向化疗后的血液学缓解与免疫触须样肾小球病良好结局相关。

研究设计与样本

  • 法国21个肾内科19年间回顾性全国队列,纳入27例成人免疫触须样肾小球病患者。

主要发现

  • 基线蛋白尿中位6.0 g/天,肾病综合征70%,镜下血尿74%,高血压56%,血肌酐中位1.5 mg/dL。
  • 19例检出单克隆丙种球蛋白血症,18例发现骨髓和/或外周血克隆性疾病。
  • 21例接受烷化剂、利妥昔单抗或硼替佐米方案化疗,18例获肾脏缓解。
  • 中位随访40个月,16例维持肾脏缓解,7例达终末期肾病,6例死亡。

关键数值与推荐

  • 肾活检示非典型膜性或膜增生性肾小球肾炎,伴微管状单克隆IgG沉积(17/27为κ型),最常见IgG1。
  • 10例检测克隆淋巴细胞中5例见相同胞质内微管结构。

临床怎么用

  • 对免疫触须样肾小球病患者应完善病理和血液学检查以寻找克隆性疾病。
  • 克隆靶向化疗后监测血液学缓解可能有助于改善肾脏结局。

局限性

  • 回顾性设计,样本量小(27例),来自单国多中心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunotactoid glomerulopathy is a rare disease defined by glomerular microtubular immunoglobulin deposits. Since management and long-term outcomes remain poorly described, we retrospectively analyzed results of 27 adults from 21 departments of nephrology in France accrued over 19 years. Inclusion criteria were presence of glomerular Congo red-negative monotypic immunoglobulin deposits with ultrastructural microtubular organization, without evidence for cryoglobulinemic glomerulonephritis. Baseline manifestations of this cohort included: proteinuria (median 6.0 g/day), nephrotic syndrome (70%), microscopic hematuria (74%) and hypertension (56%) with a median serum creatinine of 1.5 mg/dL. Nineteen patients had detectable serum and/or urine monoclonal gammopathy. A bone marrow and/or peripheral blood clonal disorder was identified in 18 cases (16 lymphocytic and 2 plasmacytic disorders). Hematologic diagnosis was chronic/small lymphocytic lymphoma in 13, and monoclonal gammopathy of renal significance in 14 cases. Kidney biopsy showed atypical membranous in 16 or membranoproliferative glomerulonephritis in 11 cases, with microtubular monotypic IgG deposits (kappa in 17 of 27 cases), most commonly IgG1. Identical intracytoplasmic microtubules were observed in clonal lymphocytes from 5 of 10 tested patients. Among 21 patients who received alkylating agents, rituximab-based or bortezomib-based chemotherapy, 18 achieved a kidney response. After a median follow-up of 40 months, 16 patients had sustained kidney response, 7 had reached end-stage kidney disease, and 6 died. Chronic/small lymphocytic lymphoma appears as a common underlying condition in immunotactoid glomerulopathy, but clonal detection remains inconstant with routine techniques in patients with monoclonal gammopathy of renal significance. Thus, early diagnosis and hematological response after clone-targeted chemotherapy was associated with favorable outcomes. Hence, thorough pathologic and hematologic workup is key to the management of immunotactoid glomerulopathy.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Javaugue V, Dufour-Nourigat L, Desport E, et al. Results of a nation-wide cohort study suggest favorable long-term outcomes of clone-targeted chemotherapy in immunotactoid glomerulopathy. Kidney Int. 2020. PMID: 32739419. doi:10.1016/j.kint.2020.06.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。